A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)

This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma subjects with induction chemotherapy as bridging therapy.

Study Overview

• Status: Not yet recruiting
• Conditions: Multiple Myeloma
• Intervention / Treatment: Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)

Detailed Description

Before enrollment, subjects will receive chemotherapy regimen of either Bortezomib-Lenalidomide-Dexamethasone (VRD), Bortezomib-Cyclophosphamide-Dexamethasone (PCD) or Bortezomib-Adriamycin-Dexamethasone (PAD) as induction therapy for 3 cycles. Evaluation will be made after 2 cycles of chemotherapy. If the subject is not intended to have stem cell transplantation or unsuitable for autologous hematopoietic stem cell transplantation (ASCT) as judged by the investigator, he/she will receive the 3rd cycle of chemotherapy. If the subject meets the inclusion criteria, he/she will be enrolled in the study.

Peripheral blood mononuclear cell (PBMC) will be collected to manufacture CT103A. After PBMC collection, the subject will receive another cycle of chemotherapy and evaluated. Lymphodepletion with fludarabine and cyclophosphamide will be performed for three consecutive days. After 1-day rest, subjects will receive a single infusion of CT103A at 1.0 ×10^6 /kg. Subjects will be followed in the study for a minimum of 2 years after CT103A infusion. Long-term follow-up for lentiviral vector safety will be followed for up to 15 years after CT103A infusion.

• Study Type: Interventional
• Enrollment (Anticipated): 20
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Lijuan Chen, M.D.; Phone Number: 025-68306091; Email: chenljb@126.com

Study Locations

• China
  • Anhui
    • Hefei, Anhui, China
      • Anhui Provincial Cancer Hospital
      • Contact: Kaiyang Ding, M.D.; Phone Number: 13966672170; Email: dingkaiy@126.com
  • Jiangsu
    • Changzhou, Jiangsu, China
      • The First People's Hospital of Changzhou
      • Contact: Weiying Gu, M.D.; Phone Number: 0519-68871092; Email: guweiying2001@163.com
    • Nanjing, Jiangsu, China
      • Jiangsu Province Hospital
      • Contact: Lijuan Chen, M.D.; Phone Number: 025-68306091; Email: chenljb@126.com
    • Nanjing, Jiangsu, China
      • Nanjing Drum Tower Hospital
      • Contact: Bing Chen, M.D.; Phone Number: 025-83106666; Email: chenbing2004@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 18 to 70 years old, male or female;

2. Newly diagnosed as high-risk multiple myeloma:

   • Revised Multiple Myeloma International Staging System (R-ISS) stage 3;
   • Double-hit or triple-hit according to FISH test.

3. Presence of measurable lesions during screening according to any of the following criteria:

   • The proportion of primitive naive or monoclonal plasma cells ≥ 5% by bone marrow cytology, bone marrow biopsy histology or flow cytometry;
   • Serum monoclonal protein (M-protein) level: M protein ≥10 g/L for IgG type, M protein ≥5g/L for IgA, IgD, IgM, and IgE type;
   • Urine M protein level ≥200 mg/24 hours;
   • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
4. ECOG score of 0 or 1;
5. Expected survival time ≥ 12 weeks;

6. Subjects must have appropriate organ functions and meet all the following laboratory test requirements before enrollment:

   • Hematology: Absolute neutrophil count (ANC) ≥ 1×10^9/L (prior growth factor support is allowed, but supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10^9/L; platelets≥75×10^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test; recombinant human erythropoietin is allowed);
   • Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN;
   • Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min.
   • Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
   • Blood oxygen saturation>91%;
   • Left ventricular ejection fraction (LVEF) ≥50%;
7. Subjects and their spouses agree to take effective tools or contraceptive measures (safe period contraception is not included) from the time the subject signs the informed consent form until one year after the CAR-T cell infusion.

Exclusion Criteria:

1. Patient who needs chronic use of immunosuppressive agents;
2. Patient with hypertension that cannot be controlled by medication;
3. Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia;
4. Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases that require drug treatment;
5. Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast;
6. Patient with a history of solid organ transplantation;
7. Patient who is suspected with or with symptoms of central nervous system invasion by plasma cell tumors;
8. Multiple myeloma patients with plasma cell leukemia;
9. Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;
10. Women who are pregnant or breastfeeding;
11. Patient with mental illness or disturbance of consciousness or central nervous system disease;
12. Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;
13. Other situations considered unsuitable by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: CT103A in Newly Diagnosed Subjects With High-risk Multiple Myeloma; Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection（CT103A）will be infused at 1.0 x 10^6 CAR+ T cells/kg in newly diagnosed subjects with high-risk multiple myeloma

Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A); CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A. CT103A will be infused at 1.0×10^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min.; Other Names: CT103A

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Minimal Residual Disease (MRD)-negative subjects	The proportion of subjects who achieve MRD-negativity after CT103A infusion.	Up to 2 years after CT103A infusion
Median progression-free survival (mPFS)	The median time from the date of CT103A infusion to the date of first disease progression or death from any cause.	Up to 2 years after CT103A infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best overall response (BOR)	The proportion of subjects who achieve stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) after CT103A infusion.	Up to 2 years after CT103A infusion
Median survival (mOS)	The median time from the date of CT103A infusion to the date of death from any reason.	Up to 2 years after CT103A infusion
Event-free survival (EFS)	The time from date of CT103A infusion to the date of death from any reason, relapse, treatment failure, disease progression or initiation of other anti-tumor treatment, whichever comes first;	Up to 2 years after CT103A infusion
Duration of response (DOR)	The time from the first assessment of sCR or CR or VGPR or PR to the first assessment of disease progression or death from any cause;	Up to 2 years after CT103A infusion
Safety endpoint	Incidence of treatment-emergent adverse events (TEAE) and Treatment-related adverse events (TRAE).	Up to 2 years after CT103A infusion
Pharmacokinetic(PK) endpoint	The maximum CT103A concentration and the copy number of the lentiviral vector (vector copy number, VCN) in peripheral blood (Cmax)	Up to 90 days after CT103A infusion
PK endpoint - Tmax	The time to reach the maximum concentration (Tmax)	Up to 90 days after CT103A infusion
PK endpoint - AUC 0 to 28d and AUC 0 to 90d	The area under the concentration time curve from time zero to day 28 (AUC0-28d) and from time zero to day 90 (AUC0-90d)	Up to 90 days after CT103A infusion
Levels of Soluable BCMA	The levels of soluble BCMA in peripheral blood at each time point.	Up to 90 days after CT103A infusion
PD endpoint	The levels of cytokines (IL-6, serum ferritin, etc.) in peripheral blood at each time point	Up to 90 days after CT103A infusion

Collaborators and Investigators

• Sponsor: Nanjing IASO Biotherapeutics Co.,Ltd
• Investigators: Principal Investigator: Lijuan Chen, M.D., The First Affiliated Hospital with Nanjing Medical University; Principal Investigator: Bing Chen, M.D., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): April 1, 2022
• Primary Completion (ANTICIPATED): April 1, 2024
• Study Completion (ANTICIPATED): April 1, 2039

Study Registration Dates

• First Submitted: November 21, 2021
• First Submitted That Met QC Criteria: January 3, 2022
• First Posted (ACTUAL): January 6, 2022

Study Record Updates

• Last Update Posted (ACTUAL): January 6, 2022
• Last Update Submitted That Met QC Criteria: January 3, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: CAR-T; treatment naive; multiple myeloma; newly diagnosed
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Multiple Myeloma; Neoplasms, Plasma Cell
• Other Study ID Numbers: CT103ACI001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No